Cash flow Yili Chuanning Biotechnology Co.,Ltd.

Equities

301301

CNE100005WX0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 2024-09-13			5-day change	1st Jan Change
10.62 ^CNY	-1.21%		-1.21%	+26.43%

Aug. 26	Yili Chuanning Biotechnology Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
Jul. 11	Yili Chuanning Biotechnology Gets Nod to Market Ursodeoxycholic Acid	MT

cf2918623973b49683404a1986c0ade.niIUFUtfXOXjlbFC7R3fdg5TlTKf7EfU78R-7_D0ZLk.0lNxZHNybqKn3OQGj2e7GmBn5HzGn3WcnaE_q7TADo3VFXZhP2gusqnR-A

Published financial data: YILI CHUANNING BIOTECHNOLOGY CO.,LTD.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: December	2019	2020	2021	2022	2023
Revenues	2.85B	3.37B	3.05B	3.57B	4.51B
Other Revenues, Total	294M	283M	177M	247M	309M
Total Revenues	3.14B	3.65B	3.23B	3.82B	4.82B
Cost of Goods Sold, Total	2.62B	3.01B	2.64B	2.9B	3.34B
Gross Profit	528M	642M	595M	921M	1.48B
Selling General & Admin Expenses, Total	132M	123M	130M	146M	166M
Provision for Bad Debts	45.26M	752K	-1.61M	14.26M	6.5M
R&D Expenses	18.18M	25.05M	32.95M	35.38M	55.26M
Other Operating Expenses	28.78M	36.14M	36.7M	54.87M	66.52M
Other Operating Expenses, Total	224M	185M	198M	250M	294M
Operating Income	303M	457M	397M	671M	1.19B
Interest Expense, Total	-190M	-174M	-177M	-142M	-87.78M
Interest And Investment Income	646K	3.11M	9.2M	5.21M	16.18M
Net Interest Expenses	-189M	-171M	-168M	-137M	-71.6M
Currency Exchange Gains (Loss)	3.65M	-8.35M	-5.37M	14.71M	12.18M
Other Non Operating Income (Expenses)	-3.51M	-1.48M	-948K	-12.49M	-1.41M
EBT, Excl. Unusual Items	115M	277M	223M	536M	1.13B
Gain (Loss) On Sale Of Investments	-	421K	548K	-8.96M	-14.73M
Gain (Loss) On Sale Of Assets	-	-	261K	-	1.34M
Asset Writedown	-4.35M	-1.41M	-5.79M	-676K	-
Other Unusual Items	-	-	-83.74M	-38.65M	5.64M
EBT, Incl. Unusual Items	110M	276M	134M	488M	1.12B
Income Tax Expense	20.04M	47.07M	22.73M	76.11M	177M
Earnings From Continuing Operations	90.22M	229M	111M	412M	941M
Net Income to Company	90.22M	229M	111M	412M	941M
Minority Interest	1.17M	-1.96K	-418	662	-997
Net Income - (IS)	91.39M	229M	111M	412M	941M
Net Income to Common Incl Extra Items	91.39M	229M	111M	412M	941M
Net Income to Common Excl. Extra Items	91.39M	229M	111M	412M	941M
Per Share Items
Net EPS - Basic	-	0.11	0.06	0.21	0.42
Basic EPS - Continuing Operations	-	0.11	0.06	0.21	0.42
Basic Weighted Average Shares Outstanding	-	2B	1.86B	1.96B	2.24B
Net EPS - Diluted	-	0.11	0.06	0.21	0.42
Diluted EPS - Continuing Operations	-	0.11	0.06	0.21	0.42
Diluted Weighted Average Shares Outstanding	-	2B	1.86B	1.96B	2.24B
Normalized Basic EPS	-	0.09	0.08	0.17	0.31
Normalized Diluted EPS	-	0.09	0.08	0.17	0.31
Dividend Per Share	-	-	-	0.09	0.22
Payout Ratio	1.13	25	150.7	34.71	30.85
Supplemental Items
EBITDA	759M	949M	920M	1.22B	1.73B
EBITA	319M	477M	419M	697M	1.21B
EBIT	303M	457M	397M	671M	1.19B
EBITDAR	764M	953M	-	1.22B	1.73B
Total Revenues (As Reported)	-	-	3.23B	3.82B	4.82B
Effective Tax Rate - (Ratio)	18.18	17.05	16.96	15.61	15.85
Current Domestic Taxes	-	-	25.67M	80.41M	187M
Total Current Taxes	28.72M	39.92M	25.67M	80.41M	187M
Deferred Domestic Taxes	-	-	-2.94M	-4.3M	-10.09M
Total Deferred Taxes	-8.68M	7.15M	-2.94M	-4.3M	-10.09M
Normalized Net Income	72.8M	173M	139M	335M	703M
Supplemental Operating Expense Items
Selling and Marketing Expenses	56.04M	15.62M	9.79M	11.46M	22.57M
General and Administrative Expenses	74.71M	105M	120M	134M	143M
Research And Development Expense From Footnotes	18.18M	25.05M	32.95M	52.76M	71.43M
Net Rental Expense, Total	4.17M	4.75M	-	5.04M	5.09M
Imputed Operating Lease Interest Expense	1.36M	1.46M	-	1.65M	1.37M
Imputed Operating Lease Depreciation	2.81M	3.29M	-	3.39M	3.72M
Maintenance & Repair Expenses, Total	137M	140M	110M	9.77M	-
Stock-Based Comp., Other (Total)	2.16M	-	-	-	22.15M
Total Stock-Based Compensation	2.16M	-	-	-	22.15M

Fiscal Period: December	2019	2020	2021	2022	2023
Assets
Cash And Equivalents	174M	510M	510M	1.63B	761M
Trading Asset Securities, Total	-	421K	1.21M	1.15M	-
Total Cash And Short Term Investments	174M	511M	511M	1.63B	761M
Accounts Receivable, Total	1.3B	1.22B	1.18B	1.42B	1.4B
Other Receivables	37.05M	1.73M	1.19M	2.59M	631K
Total Receivables	1.33B	1.22B	1.18B	1.42B	1.4B
Inventory	1.42B	1.45B	1.45B	1.38B	1.68B
Other Current Assets, Total	182M	135M	72.12M	91.25M	115M
Total Current Assets	3.11B	3.32B	3.22B	4.53B	3.96B
Gross Property Plant And Equipment	7.93B	8.27B	8.39B	8.53B	9.38B
Accumulated Depreciation	-1.5B	-1.97B	-2.47B	-2.99B	-3.51B
Net Property Plant And Equipment	6.43B	6.29B	5.92B	5.54B	5.87B
Long-term Investments	-	-	-	6.93M	6.78M
Goodwill	1.37M	1.37M	1.37M	1.37M	1.37M
Other Intangibles, Total	230M	212M	272M	283M	258M
Deferred Tax Assets Long-Term	11.17M	4.02M	6.96M	11.34M	21.65M
Deferred Charges Long-Term	25.17M	39.93M	4.72M	3.4M	2.42M
Other Long-Term Assets, Total	85.14M	54.46M	40.94M	17.97M	21.64M
Total Assets	9.89B	9.92B	9.46B	10.39B	10.14B
Liabilities
Accounts Payable, Total	212M	421M	428M	283M	480M
Accrued Expenses, Total	23.9M	23.09M	20.7M	53.46M	31.57M
Short-term Borrowings	4.77B	791M	700M	979M	851M
Current Portion of Long-Term Debt	-	628M	878M	847M	538M
Current Portion of Leases	-	-	1.02M	1.88M	3.8M
Current Income Taxes Payable	2.03M	168K	145K	24.79M	36.52M
Unearned Revenue Current, Total	6.55M	15.78M	21.26M	38M	28.94M
Other Current Liabilities	438M	522M	514M	480M	566M
Total Current Liabilities	5.46B	2.4B	2.56B	2.71B	2.54B
Long-Term Debt	-	2.85B	2.09B	1.43B	357M
Long-Term Leases	-	-	3.13M	10.2M	188M
Unearned Revenue Non Current	7.92M	7.92M	26.22M	34.24M	83.74M
Deferred Tax Liability Non Current	-	-	-	83.39K	307K
Other Non Current Liabilities	-	-	-	-	77.9K
Total Liabilities	5.46B	5.25B	4.68B	4.18B	3.17B
Common Stock, Total	4B	2B	2B	2.22B	2.22B
Additional Paid In Capital	410M	2.43B	2.43B	3.23B	3.25B
Retained Earnings	20.81M	229M	341M	752M	1.49B
Total Common Equity	4.43B	4.66B	4.77B	6.2B	6.96B
Minority Interest	-	6M	6M	6M	12.87M
Total Equity	4.43B	4.67B	4.78B	6.21B	6.97B
Total Liabilities And Equity	9.89B	9.92B	9.46B	10.39B	10.14B
Supplemental Items
ECS Total Shares Outstanding on Filing Date	-	2B	2B	2.22B	2.22B
ECS Total Common Shares Outstanding	-	2B	-	2.22B	2.22B
Book Value / Share	-	2.33	2.39	2.79	3.13
Tangible Book Value	4.2B	4.45B	4.5B	5.92B	6.7B
Tangible Book Value Per Share	-	2.22	2.25	2.66	3.01
Total Debt	4.77B	4.27B	3.67B	3.27B	1.94B
Net Debt	4.6B	3.75B	3.16B	1.63B	1.18B
Debt Equivalent Oper. Leases	33.35M	38.01M	-	40.34M	40.72M
Minority Interest, Total (Incl. Fin. Div)	-	6M	6M	6M	12.87M
Equity Method Investments, Total	-	-	-	6.93M	6.78M
Account Code - Inventory Valuation	-	6	-	6	6
Inventories - Raw Materials, Total	789M	794M	913M	841M	1.04B
Inventories - Work In Process, Total	41.31M	48.54M	70.36M	47.63M	56.93M
Inventories - Finished Goods, Total	513M	526M	401M	435M	531M
Inventories - Others	80.2M	84.17M	76.1M	72.28M	66.22M
Buildings, Total	2.4B	2.46B	2.56B	2.64B	2.78B
Machinery, Total	5.15B	5.45B	5.73B	5.82B	5.86B
Full Time Employees	-	-	-	2.78K	2.88K
Accumulated Allowance for Doubtful Accounts (Supple)	56.43M	6.33M	4.38M	20.44M	27.09M

Fiscal Period: December	2019	2020	2021	2022	2023
Net Income	91.39M	229M	111M	412M	941M
Depreciation & Amortization - CF	440M	472M	502M	521M	524M
Amortization of Goodwill and Intangible Assets - (CF)	15.82M	19.18M	21.75M	26.11M	26.15M
Depreciation & Amortization, Total	456M	491M	524M	548M	550M
Amortization of Deferred Charges, Total - (CF)	-	527K	656K	1.47M	1.04M
(Gain) Loss From Sale Of Asset	-	-	-261K	-	-1.34M
(Gain) Loss on Sale of Investments - (CF)	-	-2.08M	-3.89M	3.76M	4.57M
Asset Writedown & Restructuring Costs	4.35M	1.41M	16.82M	31.5M	50.44M
Provision and Write-off of Bad Debts	45.26M	752K	-	-	-
Other Operating Activities, Total	190M	177M	168M	138M	84.48M
Change In Accounts Receivable	-104M	163M	78.13M	-424M	-275M
Change In Inventories	-420M	-32.43M	-7.75M	53.31M	-335M
Change In Accounts Payable	-401M	-386M	-80.07M	-63.77M	265M
Change In Deferred Taxes	-8.68M	7.15M	-2.94M	-4.3M	-10.09M
Change in Other Net Operating Assets	58.98K	-	-660K	-3.46M	17.9M
Cash from Operations	-147M	650M	803M	692M	1.29B
Capital Expenditure	-65.44M	-89.19M	-52.27M	-47.2M	-345M
Sale of Property, Plant, and Equipment	-	-	766K	-	23.78K
Investment in Marketable and Equity Securities, Total	-	-	3.34M	-7M	0
Other Investing Activities, Total	-	1.66M	-	-	-8.27M
Cash from Investing	-65.44M	-87.53M	-48.16M	-54.2M	-353M
Long-Term Debt Issued, Total	939M	4.26B	933M	1.16B	852M
Total Debt Issued	939M	4.26B	933M	1.16B	852M
Long-Term Debt Repaid, Total	-687M	-4.43B	-1.51B	-1.58B	-2.37B
Total Debt Repaid	-687M	-4.43B	-1.51B	-1.58B	-2.37B
Issuance of Common Stock	-	-	-	1.05B	-
Common Dividends Paid	-1.03M	-57.26M	-168M	-143M	-290M
Common & Preferred Stock Dividends Paid	-1.03M	-57.26M	-168M	-143M	-290M
Other Financing Activities, Total	-17.28M	6.65M	-	-13.42M	-1.07M
Cash from Financing	234M	-219M	-749M	476M	-1.81B
Foreign Exchange Rate Adjustments	1.8M	-5.13M	-6.51M	4.1M	3.33M
Net Change in Cash	23.33M	339M	-759K	1.12B	-866M
Supplemental Items
Cash Income Tax Paid (Refund)	70.7M	175M	135M	284M	529M
Levered Free Cash Flow	61.73M	1.01B	712M	539M	877M
Unlevered Free Cash Flow	180M	1.12B	823M	627M	932M
Change In Net Working Capital	402M	-432M	-102M	294M	37.47M
Net Debt Issued / Repaid	252M	-168M	-581M	-418M	-1.52B

Fiscal Period: December	2019	2020	2021	2022	2023
Profitability
Return on Assets	1.95	2.89	2.56	4.22	7.22
Return on Total Capital	2.1	3.15	2.85	4.68	8.06
Return On Equity %	2.05	5.03	2.36	7.49	14.27
Return on Common Equity	2.08	5.04	2.36	7.5	14.29
Margin Analysis
Gross Profit Margin %	16.79	17.59	18.41	24.11	30.69
SG&A Margin	4.21	3.36	4.03	3.82	3.44
EBITDA Margin %	24.16	26	28.46	31.85	35.86
EBITA Margin %	10.16	13.06	12.95	18.24	25.14
EBIT Margin %	9.65	12.53	12.28	17.56	24.6
Income From Continuing Operations Margin %	2.87	6.28	3.45	10.77	19.5
Net Income Margin %	2.91	6.28	3.45	10.77	19.5
Net Avail. For Common Margin %	2.91	6.28	3.45	10.77	19.5
Normalized Net Income Margin	2.32	4.74	4.31	8.77	14.58
Levered Free Cash Flow Margin	1.96	27.73	22.03	14.1	18.19
Unlevered Free Cash Flow Margin	5.73	30.71	25.45	16.42	19.32
Asset Turnover
Asset Turnover	0.32	0.37	0.33	0.38	0.47
Fixed Assets Turnover	0.49	0.57	0.53	0.67	0.85
Receivables Turnover (Average Receivables)	2.41	2.67	2.55	2.75	3.2
Inventory Turnover (Average Inventory)	2.16	2.1	1.82	2.04	2.18
Short Term Liquidity
Current Ratio	0.57	1.38	1.25	1.67	1.56
Quick Ratio	0.28	0.72	0.66	1.13	0.85
Operating Cash Flow to Current Liabilities	-0.03	0.27	0.31	0.26	0.51
Days Sales Outstanding (Average Receivables)	151.43	136.87	143.26	132.52	114.02
Days Outstanding Inventory (Average Inventory)	169.3	174.69	200.86	178.57	167.05
Average Days Payable Outstanding	22.21	38.14	58.6	45.83	38.3
Cash Conversion Cycle (Average Days)	298.51	273.42	285.51	265.26	242.77
Long Term Solvency
Total Debt/Equity	107.73	91.41	76.92	52.59	27.8
Total Debt / Total Capital	51.86	47.76	43.48	34.47	21.75
LT Debt/Equity	-	61	43.86	23.16	7.82
Long-Term Debt / Total Capital	-	31.87	24.79	15.18	6.12
Total Liabilities / Total Assets	55.22	52.97	49.51	40.23	31.22
EBIT / Interest Expense	1.6	2.63	2.24	4.71	13.51
EBITDA / Interest Expense	4.01	5.46	5.21	8.56	19.78
(EBITDA - Capex) / Interest Expense	3.66	4.95	4.91	8.23	15.85
Total Debt / EBITDA	6.29	4.5	3.99	2.68	1.12
Net Debt / EBITDA	6.06	3.96	3.44	1.34	0.68
Total Debt / (EBITDA - Capex)	6.88	4.96	4.23	2.79	1.39
Net Debt / (EBITDA - Capex)	6.63	4.37	3.64	1.39	0.85
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	-6.15	16.1	-11.44	18.21	26.24
Gross Profit, 1 Yr. Growth %	-27.56	21.61	-7.31	54.79	59.02
EBITDA, 1 Yr. Growth %	-26.26	24.94	-3.05	32.29	42.16
EBITA, 1 Yr. Growth %	-46.58	49.3	-12.18	66.51	73.95
EBIT, 1 Yr. Growth %	-48.01	50.76	-13.26	69.06	76.86
Earnings From Cont. Operations, 1 Yr. Growth %	-76.92	153.84	-51.38	269.58	128.56
Net Income, 1 Yr. Growth %	-76.56	150.58	-51.38	269.58	128.56
Normalized Net Income, 1 Yr. Growth %	-70.02	137.86	-19.59	140.54	105.49
Diluted EPS Before Extra, 1 Yr. Growth %	-	-	-45.45	250	100
Accounts Receivable, 1 Yr. Growth %	21.65	-5.97	-3.44	20.29	-0.96
Inventory, 1 Yr. Growth %